Entera Bio Ltd. Current Part of Taxes to Pay

Current Part of Taxes to Pay of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Part of Taxes to Pay growth rates and interactive chart.


Highlights and Quick Summary

  • Current Part of Taxes to Pay for the quarter ending September 29, 2018 was $0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly Current Part of Taxes to Pay decreased by NaN%
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Part of Taxes to Pay of Entera Bio Ltd.

Most recent Current Part of Taxes to Payof ENTX including historical data for past 10 years.

Interactive Chart of Current Part of Taxes to Pay of Entera Bio Ltd.

Entera Bio Ltd. Current Part of Taxes to Pay for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2018 $0.0 $0.0 $0.0
2017 $0.0

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.